TIDMPRTC
PureTech Health PLC
21 March 2019
21 March 2019
PureTech Health plc
PureTech's Affiliate Gelesis Announces Three Presentations at
Endocrine Society Annual Meeting
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced
that its affiliate Gelesis will deliver three poster presentations
around its proprietary hydrogel platform at the Endocrine Society
Annual Meeting (ENDO) in New Orleans from 23-26 March.
Eric Elenko, PhD, chief innovation officer at PureTech Health,
said: "We're proud of Gelesis' strong presence at The Endocrine
Society Annual Meeting, one of the premiere forums for scientific
exchange around obesity and metabolic disorders. These three
posters provide additional support for the therapeutic potential of
the Gelesis platform across a range of conditions."
The full text announcement from Gelesis is as follows:
Gelesis Announces Three Presentations at Annual Endocrine
Society Meeting
BOSTON, March 21, 2019 - Gelesis, a biotechnology company
developing first-in-class mechanotherapeutics to treat obesity and
other chronic diseases related to the gastrointestinal (GI) tract,
today announced the Company will deliver three poster presentations
at ENDO, the Endocrine Society Annual Meeting, held in New Orleans
from March 23-26.
Two of the presentations will share expanded clinical data from
the pivotal study of Gelesis100, an oral, non-systemic approach to
weight loss. A third will highlight preclinical data suggesting a
different product candidate derived from Gelesis' proprietary
hydrogel platform can restore gut barrier function in mice with
severe gut wall injury.
"We are pleased to share expanded clinical data which seeks to
address crucial public health issues associated with overweight and
obesity. We are also excited to present our latest research on
leveraging our hydrogel technology in chronic diseases of the GI
system," said Harry L. Leider, MD, MBA, FACPE, Chief Medical
Officer of Gelesis. "We look forward to discussing our findings
with the scientific community."
Details of the presentations are as follows:
Poster Title: Gelesis100 Reduces Insulin Resistance in Patients
Who Are Overweight or Have Obesity with High Insulin Resistance:
Results of the GLOW Study
Poster Session: P50. Obesity Mechanisms and Treatments
Potpourri
Date and Time: March 25, 2019, (1:00 - 3:00 PM)
Poster Location: Poster Board #MON-112, ENDO Expo Hall, Ernest
N. Morial Convention Center
Poster Title: Elevated Fasting Plasma Glucose Predicts Higher
Odds for Becoming a Super-Responder with Gelesis100 in the GLOW
Pivotal Weight-Loss Study
Poster Session: P05. Obesity Comorbidities and Therapies
Date and Time: Saturday, March 23, 2019 (1:00 - 3:00 PM)
Poster Location: Poster Board # SAT-LB023, ENDO Expo Hall,
Ernest N. Morial Convention Center
Poster Title: Gelesis Novel, Non-Systemic, Superabsorbent
Hydrogel Improves Intestinal Barrier Function in Intestinal Injury
Pre-Clinical Model
Poster Session: P50. Obesity Mechanisms and Treatments
Potpourri
Date and Time: Monday, March 25, 2019 (1:00 - 3:00 PM)
Poster Location: Poster Board # MON-LB022, ENDO Expo Hall,
Ernest N. Morial Convention Center
About Gelesis 100
Gelesis100 is a non-systemic, superabsorbent hydrogel in
development for the potential treatment of overweight or obesity.
It is made from two naturally derived building blocks, modified
cellulose cross-linked with citric acid, that create a
three-dimensional matrix. Orally administered in capsules with
water before a meal, Gelesis100 particles rapidly absorb water in
the stomach and homogenously mix with ingested foods. When
hydrated, Gelesis100 occupies about one-fourth of the average
stomach volume. Rather than forming one large mass, it creates
thousands of small individual gel pieces with the elasticity
(firmness) of solid ingested foods (e.g., vegetables) without
caloric value. Gelesis100 maintains its three-dimensional structure
and mechanical properties during transit through the small
intestine. Once it arrives in the large intestine, the hydrogel is
partially broken down by enzymes and loses its three-dimensional
structure along with most of its absorption capacity. The released
water is reabsorbed in the large intestine, and the remaining
cellulosic material is expelled in the faeces. Gelesis100 is
considered a medical device because it achieves its primary
intended purpose through mechanical modes of action consistent with
mechanobiology constructs. Gelesis100 received a Non-Significant
Risk (NSR) designation by the FDA.
This investigational product has been studied in more than 450
patients (excluding patients treated by placebo) across five
clinical studies throughout the United States, Canada, and Europe.
Other than an increase in overall gastrointestinal adverse events
(AEs), most of which were assessed as mild, there was no difference
in the incidence and severity of AEs between the Gelesis100 and
placebo groups. In both treatment groups, most AEs were mild or
moderate in intensity. No serious adverse events were observed in
the Gelesis100 group. Gelesis100 is pending De Novo clearance and
is not available for sale in the United States.
About Gelesis
Gelesis is developing a novel mechanobiology platform technology
to treat obesity and other chronic diseases related to the GI
pathway. Gelesis' proprietary approach is designed to act
mechanically in the GI pathway to potentially alter the course of
chronic diseases. In September 2017, Gelesis completed a pivotal
trial for weight loss evaluating its lead investigational product
candidate Gelesis100. Additionally, Gelesis is conducting a
proof-of-concept study for its second candidate, Gelesis200, which
is optimised for weight loss and glycaemic control in patients with
type 2 diabetes and prediabetes. Novel hydrogel mechanotherapeutics
based on the Gelesis platform technology are also being advanced
through a pipeline with preclinical studies in other GI-related
conditions such as non-alcoholic fatty liver disease (NAFLD),
non-alcoholic steatohepatitis (NASH), and inflammatory bowel
disease (IBD).
The Gelesis executive and advisory team includes some of the
world's leading experts in obesity, chronic disease research, and
materials science. Gelesis was co-founded by PureTech Health (LSE:
PRTC), an advanced, clinical-stage biopharmaceutical company. For
more information, visit www.gelesis.com or connect with us on
Twitter @GelesisInc.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms with
two product candidates that have been filed with the US Food and
Drug Administration (FDA) for review and other novel pre-clinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAEDFALPNEEF
(END) Dow Jones Newswires
March 21, 2019 03:02 ET (07:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024